{"eu_number": "EU-1-21-1541", "parse_date": "2022-12-28 18:24:48.103704", "decisions": [{"pdf_file": "EU-1-21-1541_h_dec_0.pdf", "eu_aut_date": "0001-01-01", "eu_brand_name_initial": "DAS", "eu_brand_name_current": "Not parsed", "active_substance": "__SCRAPER_NOT_FOUND__", "eu_nas": "attribute not available on release", "eu_atmp": "attribute not available on release", "eu_od_initial": "attribute not available on release", "eu_mah_initial": "__SCRAPER_NOT_FOUND__", "eu_aut_type_initial": "attribute not available on release", "eu_aut_type_current": "Not parsed"}], "annexes": [{"pdf_file": "EU-1-21-1541_h_anx_0.pdf", "xml_file": "EU-1-21-1541_h_anx_0.xml", "is_initial": true, "creation_date": "D:20220222113610+05'30'", "modification_date": "D:20220222114537+05'30'", "eu_aut_type_initial": "standard", "eu_med_type": "small molecule", "eu_indication_initial": "dasatinib accordpharma is indicated for the treatment of adult patients with: \uf0a7 newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. \n \uf0a7 chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. \n \uf0a7 ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.\n\n dasatinib accordpharma is indicated for the treatment of paediatric patients with: \n \uf0a7 newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. \n \uf0a7 newly diagnosed ph+ all in combination with chemotherapy.\n"}], "epars": [{"pdf_file": "EU-1-21-1541_h_public-assessment-report.pdf", "ema_procedure_start_initial": "2019-06-03", "chmp_opinion_date": "2022-01-27", "eu_legal_basis": ["article 10.1"], "eu_prime_initial": "False", "ema_rapp": "john joseph borg", "ema_corapp": "__SCRAPER_NOT_FOUND__", "ema_reexamination": "False", "eu_accel_assess_g": "False"}], "omars": [], "odwars": []}